170 related articles for article (PubMed ID: 25840669)
1. The power of phase II end-points for different possible mechanisms of action of an experimental treatment.
Wason JM; Dentamaro A; Eisen TG
Eur J Cancer; 2015 May; 51(8):984-92. PubMed ID: 25840669
[TBL] [Abstract][Full Text] [Related]
2. Improving phase II oncology trials using best observed RECIST response as an endpoint by modelling continuous tumour measurements.
Lin CJ; Wason JMS
Stat Med; 2017 Dec; 36(29):4616-4626. PubMed ID: 28850689
[TBL] [Abstract][Full Text] [Related]
3. Resampling the N9741 trial to compare tumor dynamic versus conventional end points in randomized phase II trials.
Sharma MR; Gray E; Goldberg RM; Sargent DJ; Karrison TG
J Clin Oncol; 2015 Jan; 33(1):36-41. PubMed ID: 25349295
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of objective response, disease control and progression-free survival as surrogate end-points for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials.
Nie RC; Chen FP; Yuan SQ; Luo YS; Chen S; Chen YM; Chen XJ; Chen YB; Li YF; Zhou ZW
Eur J Cancer; 2019 Jan; 106():1-11. PubMed ID: 30453169
[TBL] [Abstract][Full Text] [Related]
5. Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer.
Karrison TG; Maitland ML; Stadler WM; Ratain MJ
J Natl Cancer Inst; 2007 Oct; 99(19):1455-61. PubMed ID: 17895472
[TBL] [Abstract][Full Text] [Related]
6. Validation of novel imaging methodologies for use as cancer clinical trial end-points.
Sargent DJ; Rubinstein L; Schwartz L; Dancey JE; Gatsonis C; Dodd LE; Shankar LK
Eur J Cancer; 2009 Jan; 45(2):290-9. PubMed ID: 19091547
[TBL] [Abstract][Full Text] [Related]
7. Directional inconsistency between Response Evaluation Criteria in Solid Tumors (RECIST) time to progression and response speed and depth.
Johnson K; Gomez A; Burton J; White D; Chakravarty A; Schmid A; Bottino D
Eur J Cancer; 2019 Mar; 109():196-203. PubMed ID: 30738696
[TBL] [Abstract][Full Text] [Related]
8. Resampling phase III data to assess phase II trial designs and endpoints.
Sharma MR; Karrison TG; Jin Y; Bies RR; Maitland ML; Stadler WM; Ratain MJ
Clin Cancer Res; 2012 Apr; 18(8):2309-15. PubMed ID: 22287601
[TBL] [Abstract][Full Text] [Related]
9. ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).
Emmett L; Subramaniam S; Joshua AM; Crumbaker M; Martin A; Zhang AY; Rana N; Langford A; Mitchell J; Yip S; Francis R; Hofman MS; Sandhu S; Azad A; Gedye C; McJannett M; Stockler MR; Davis ID;
BJU Int; 2021 Nov; 128(5):642-651. PubMed ID: 34028967
[TBL] [Abstract][Full Text] [Related]
10. Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials.
London WB; Bagatell R; Weigel BJ; Fox E; Guo D; Van Ryn C; Naranjo A; Park JR
Cancer; 2017 Dec; 123(24):4914-4923. PubMed ID: 28885700
[TBL] [Abstract][Full Text] [Related]
11. Alternative clinical end points in rectal cancer--are we getting closer?
Glynne-Jones R; Mawdsley S; Pearce T; Buyse M
Ann Oncol; 2006 Aug; 17(8):1239-48. PubMed ID: 16873440
[TBL] [Abstract][Full Text] [Related]
12. Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Grünwald V; Lin X; Kalanovic D; Simantov R
Eur Urol; 2016 Dec; 70(6):1006-1015. PubMed ID: 27238653
[TBL] [Abstract][Full Text] [Related]
13. Comparative Effects of CT Imaging Measurement on RECIST End Points and Tumor Growth Kinetics Modeling.
Li CH; Bies RR; Wang Y; Sharma MR; Karovic S; Werk L; Edelman MJ; Miller AA; Vokes EE; Oto A; Ratain MJ; Schwartz LH; Maitland ML
Clin Transl Sci; 2016 Feb; 9(1):43-50. PubMed ID: 26790562
[TBL] [Abstract][Full Text] [Related]
14. Comparison of error rates in single-arm versus randomized phase II cancer clinical trials.
Tang H; Foster NR; Grothey A; Ansell SM; Goldberg RM; Sargent DJ
J Clin Oncol; 2010 Apr; 28(11):1936-41. PubMed ID: 20212253
[TBL] [Abstract][Full Text] [Related]
15. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase II/III confirmatory treatment selection design with a change of survival end points: Statistical design of Radiation Therapy Oncology Group 1216.
Zhang QE; Wu Q; Harari PM; Rosenthal DI
Head Neck; 2019 Jan; 41(1):37-45. PubMed ID: 30549358
[TBL] [Abstract][Full Text] [Related]
17. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
[TBL] [Abstract][Full Text] [Related]
18. Characterizing tumor shrinkage as a measure of clinical benefit for immune checkpoint inhibitors.
Kelleher T; Cai J; Botwood NA; Labriola DF
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33558277
[TBL] [Abstract][Full Text] [Related]
19. The choice of test in phase II cancer trials assessing continuous tumour shrinkage when complete responses are expected.
Wason JM; Mander AP
Stat Methods Med Res; 2015 Dec; 24(6):909-19. PubMed ID: 22179821
[TBL] [Abstract][Full Text] [Related]
20. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
